Search
Researchers from the Wal-yan Respiratory Research Centre are collaborating with Virex Pharma to undertake vital research into a potential breakthrough treatment for RSV infections in young children, thanks to a $499,241 grant awarded by the WA Department of Health Innovation Seed Fund.
The Wal-yan Respiratory Research Centre is proud to have a team of researchers taking part in, and contributing to, the outstanding scientific programme of the European Respiratory Society International Congress, taking place in Milan.
Flare-ups of asthma are usually brought on by respiratory infections, such as the common cold, and are one of the most common reasons for a child to miss school or require emergency care.
We tested the hypothesis that treatment of CF epithelial cells with ivacaftor (Iva) or ivacaftor/lumacaftor (Iva/Lum) would improve control of rhinovirus infection.
A study which set out to determine ways to predict the long-term lung health of young adults born very preterm has shown that a childhood history of respiratory hospital admission should be a key consideration in the management of preterm children and adults.
A new research project – the WA Paediatric Bronchiectasis Cohort Study – officially commenced this month with the aim of looking at children with bronchiectasis in Western Australia, like nine-year-old Holly (pictured), to better understand how this disease develops during childhood.
Dr Daniel Laucirica, a research officer with the Wal-yan Respiratory Research Centre, will undertake new research into potential treatment strategies to prevent lung damage in people with cystic fibrosis (CF), under the mentorship of Associate Professor Anthony Kicic - made possible by a Vertex Cyst
A new study has found a common asthma drug is effective for some very premature babies who go on to suffer from lung complications.
Two outstanding researchers from the Wal-yan Respiratory Research Centre have been awarded a 2022 Innovation Fellowship supported by the WA Government's Future Health Research and Innovation (FHRI) Fund.
Access to phage therapy, a treatment option for antibiotic resistant superbugs, is now one step closer for people with CF in WA thanks to a $500,000 donation from Conquer Cystic Fibrosis to the Wal-yan Respiratory Research Centre.